• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
FIGURE 2. Structure of the decision model, assuming patients continue beyond 3 months if they achieve a PsARC response.

FIGURE 2Structure of the decision model, assuming patients continue beyond 3 months if they achieve a PsARC response

From: 4, Assessment of cost-effectiveness evidence

Cover of Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation
Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.10.
Rodgers M, Epstein D, Bojke L, et al.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.